ProscaVax Vaccine Stopped Prostate Cancer Progression in 80% of Patients, Phase 1 Trial Shows

ProscaVax Vaccine Stopped Prostate Cancer Progression in 80% of Patients, Phase 1 Trial Shows
Six injections of OncBioMune Pharmaceuticals‘ prostate cancer vaccine ProscaVax stopped the progression of the disease in 80 percent of patients in a Phase 1 clinical trial, the company announced. The results applied to patients who had been treated for 19 weeks. All the participants had cancer that had returned after other treatment regimens. “All the data to date

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

5 comments

    • Alice Melão says:

      Dear Sandy, the ProscaVax vaccine is not yet available and is still under evaluation in clinical trials. Only one trial on this vaccine is ongoing, and is being conducted in San Diego. For you to find clinical studies being conducted in you country in the https://clinicaltrials.gov website. Here you can find all information regarding location, contacts, eligibility, and information on trial design and protocol.

    • Alice Melão says:

      Dear Anthony, the company has not released a timeline of development of this investigative therapy. However, additional studies are still necessary before regulatory approvals are granted.

Leave a Comment

Your email address will not be published. Required fields are marked *